Leucine

Leucine

SCHEMBL4612424

CC(C)C[C@H](N)C(=O)O.NCC(=O)O.NCC(=O)O.NCC(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.49
SLC1A3 P43003 3/20 0.41
SLC1A2 P43004 3/20 0.41
SLC1A1 P43005 2/20 0.36
DPP4 P27487 3/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
REN P00797 1/20 0.33
PRCP P42785 1/20 0.33
NOS2 P35228 2/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL21382169 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL28392735 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL3183643 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL27683459 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL5889661 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL3089172 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL23091356 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL1675456 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL6534720 0.97 SLC7A5 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL7110075 0.97 SLC7A5 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1054677-B1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES CONNECTIVE TISSUE IMAGINEERING (US) 2008-10-22 EP claimed
EP-1064010-B1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2008-02-20 EP claimed
EP-1064010-A4 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2004-10-06 EP claimed
US-6777389-B1 INHIBITING CUTANEOUS EFFECTS OF AGING CONNECTIVE TISSUE IMAGINEERING LLC 2004-08-17 US claimed
CN-1300220-A Peptide compositions and formulations and use of same MRS LTD (US) 2001-06-20 CN claimed
EP-1064010-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME Mrs, Llc (US) 2001-01-03 EP claimed
WO-1999045941-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME MRS, LLC (US) 1999-09-16 WO claimed
EP-1054677-B1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES CONNECTIVE TISSUE IMAGINEERING (US) 2008-10-22 EP disclosed
EP-1064010-B1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2008-02-20 EP disclosed
EP-1392346-A4 COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE CONNECTIVE TISSUE IMAGINEERING (US) 2006-10-25 EP disclosed
US-6962904-B1 Elastin peptide analogs and uses thereof CONNECTIVE TISSUE IMAGINEERING (US) 2005-11-08 US disclosed
EP-1054677-A4 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES MRS LLC (US) 2005-07-27 EP disclosed
US-20050054578-A1 Elastin peptide analogs and uses thereof SANDBERG LAWRENCE B (US) 2005-03-10 US disclosed
US-6506731-B1 Peptide or peptide-like compound(s) of the present invention appear to aid the elasticity and/or turgor of the skin CONNECTIVE TISSUE IMAGINEERING LLC 2003-01-14 US disclosed
WO-2001091700-A2 COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE CONNECTIVE TISSUE IMAGINEERING LLC (US) 2001-12-06 WO disclosed
WO-2000028996-A9 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES MRS LLC (US) 2001-08-02 WO disclosed
EP-1064010-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME Mrs, Llc (US) 2001-01-03 EP disclosed
EP-1054677-A1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES Mrs, Llc (US) 2000-11-29 EP disclosed
WO-2000028996-A1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES MRS, LLC (US) 2000-05-25 WO disclosed
WO-1999045941-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME MRS, LLC (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054578-A1 Elastin peptide analogs and uses thereof ELANE, CUTA, ENPEP SLC7A5 2652/4885SLC1A3 4341/4885SLC1A2 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.